UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 422,290 Shares of Boston Scientific Corporation $BSX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in Boston Scientific Corporation (NYSE:BSX) by 3.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,091,481 shares of the medical equipment provider’s stock after selling 422,290 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.90% of Boston Scientific worth $558,744,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Renaissance Group LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at $28,064,000. Perigon Wealth Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth about $883,000. Y Intercept Hong Kong Ltd raised its stake in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after acquiring an additional 670,060 shares during the period. Wealthfront Advisers LLC purchased a new stake in Boston Scientific during the second quarter valued at about $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab lifted its holdings in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $46.82 on Monday. The company’s fifty day moving average price is $46.56 and its 200-day moving average price is $56.53. The firm has a market capitalization of $67.85 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent research reports. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Jefferies Financial Group cut their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Bank of America reduced their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a report on Thursday, May 28th. Finally, Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $71.62.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.